Owners, management and financials
CVR: 19389006
DKK 3,230,179
Gross profit
Net result: DKK 350,332
Desitin Arzneimittel GmbH (100%)
CVR · view owners
Eli Lønne
Board: Philipp Andreas Bloching (chair) and 2 members
CVR · view management
Active
Founded 1 July 1996
CVR · view overview
1 employee
CVR · 2026
Director role ended: Alexander Arnkværn Berg
CVR · 30/11/2020
View the full event history
DESITIN PHARMA A/S is a Danish company of the type Aktieselskab based in København V, founded in 1996. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Eli Lønne. The board consists of Philipp Andreas Bloching (chair), Eli Lønne and Oliver Christoph. The company is owned by Desitin Arzneimittel GmbH. The company has 1 employee (2026). In 2026, the company reported a gross profit of DKK 3,230,179 and a net result of DKK 350,332 compared with DKK 288,733 the year before. Equity in the 2026 report amounted to DKK 7,394,472.
Source: annual report 2026, Danish Business Authority
The financial health of DESITIN PHARMA A/S appears stable, with a notable increase in gross profit and profit margins over the past few years. In 2026, the company reported a gross profit of 3,230,179 DKK and a profit of 350,332 DKK, reflecting a positive trend from 2,151,761 DKK in gross profit and 288,733 DKK in profit in 2025. Equity has also shown growth, reaching 7,394,472 DKK in 2026, indicating a solid financial foundation. However, the absence of revenue data raises concerns about overall sales performance, which could impact future growth potential in the competitive pharmaceutical distribution industry.
AI-generated summary · Generated 04/11/2026
Selskabets formål er at markedsføre samt formidle salg af lægemidler samt hermed beslægtet virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202601/10/2025 – 30/09/2026 | 3.2M | 350K | 8.3M | 7.4M | 2 | |
| 202501/10/2024 – 30/09/2025 | 2.2M | 289K | 7.7M | 7M | 2 | |
| 202401/10/2023 – 30/09/2024 | 2.1M | 286K | 7.2M | 6.8M | 2 | |
| 202301/10/2022 – 30/09/2023 | 3M | 2.6M | 9.8M | 8.6M | 2 | |
| 202201/10/2021 – 30/09/2022 | 3.5M | 346K | 7M | 6.4M | 2 | |
| 202101/10/2020 – 30/09/2021 | 3.8M | 353K | 7.4M | 6.4M | 2 | |
| 202001/10/2019 – 30/09/2020 | 4.2M | 430K | 7.6M | 6.1M | 3 | |
| 201901/10/2018 – 30/09/2019 | 5.7M | 541K | 7.3M | 5.7M | 4 | |
| 201801/10/2017 – 30/09/2018 | 6M | 1.5M | 6.6M | 5.1M | - | |
| 201701/10/2016 – 30/09/2017 | 4.6M | 630K | 4.5M | 3.6M | - | |
| 201601/10/2015 – 30/09/2016 | 5.6M | 1.2M | 4.9M | 3.7M | - | |
| 201501/10/2014 – 30/09/2015 | 7.4M | 2.4M | 5.4M | 3.7M | - | |
| 201401/10/2013 – 30/09/2014 | 958K EUR | 287K EUR | 526K EUR | 379K EUR | - | |
| 201301/10/2012 – 30/09/2013 | 881K EUR | 209K EUR | 543K EUR | 342K EUR | - |
Compared to 404 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
3 public tenders won
Sources: TED (the EU tender database) and udbud.dk
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringThe CVR number of DESITIN PHARMA A/S is 19389006.
DESITIN PHARMA A/S is owned by Desitin Arzneimittel GmbH.
The management of DESITIN PHARMA A/S consists of Eli Lønne.
The board of DESITIN PHARMA A/S consists of Philipp Andreas Bloching, Eli Lønne and Oliver Christoph, with Philipp Andreas Bloching as chair.
In 2026, DESITIN PHARMA A/S reported a gross profit of DKK 3,230,179.
DESITIN PHARMA A/S had 1 employee in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
DESITIN PHARMA A/S has published its annual report for 2026. Gross profit came to DKK 3,230,179, and the net result was DKK 350,332.
DESITIN PHARMA A/S has won the tender "Amgros 2027 1.615.b" issued by Amgros I/S worth 67,284,330 DKK.
Contact info changed: new phone: 33730073, new email: [email protected] (August 11, 2026).
As of August 6, 2026, Oliver Christoph has joined the board of directors of DESITIN PHARMA A/S.
As of August 6, 2026, Katrin Elisabeth Thieken has left the board of directors of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2025. Gross profit came to DKK 2,151,761, and the net result was DKK 288,733.
DESITIN PHARMA A/S has won the tender "Amgros 2026 1.615.b" issued by Amgros I/S worth 48,195,968 DKK.
DESITIN PHARMA A/S has published its annual report for 2024. Gross profit came to DKK 2,123,028, and the net result was DKK 285,567.
DESITIN PHARMA A/S has won the tender "Amgros 2025 1.1303.b" issued by Amgros I/S worth 14,267,938 DKK.
As of October 1, 2024, Beierholm Godkendt Revisionspartnerselskab has been appointed auditor of DESITIN PHARMA A/S.
As of October 1, 2024, EMIT P/S has stepped down as auditor of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2023. Gross profit came to DKK 3,043,433, and the net result was DKK 2,606,443.
As of November 10, 2023, EMIT P/S has been appointed auditor of DESITIN PHARMA A/S.
As of November 10, 2023, J&P Invest, Kbh. ApS has stepped down as auditor of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2022. Gross profit came to DKK 3,469,531, and the net result was DKK 346,301.
As of July 5, 2022, Philipp Andreas Bloching has joined the board of directors of DESITIN PHARMA A/S.
As of July 5, 2022, Katrin Elisabeth Thieken has joined the board of directors of DESITIN PHARMA A/S.
As of July 5, 2022, Martin Schütt has left the board of directors of DESITIN PHARMA A/S.
As of July 5, 2022, Christoph Steinschulte has left the board of directors of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2021. Gross profit came to DKK 3,788,057, and the net result was DKK 353,005.
DESITIN PHARMA A/S has published its annual report for 2020. Gross profit came to DKK 4,229,777, and the net result was DKK 430,256.
As of November 30, 2020, Eli Lønne has joined the board of directors of DESITIN PHARMA A/S.
As of November 30, 2020, Alexander Arnkværn Berg has left the board of directors of DESITIN PHARMA A/S.
As of November 30, 2020, Eli Lønne is registered as director of DESITIN PHARMA A/S.
As of November 30, 2020, Alexander Arnkværn Berg has stepped down as director of DESITIN PHARMA A/S.
As of February 17, 2020, Christoph Steinschulte has joined the board of directors of DESITIN PHARMA A/S.
As of February 17, 2020, Christian Eric Schmolck has left the board of directors of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2019. Gross profit came to DKK 5,696,243, and the net result was DKK 540,753.
As of July 15, 2019, Alexander Arnkværn Berg has joined the board of directors of DESITIN PHARMA A/S.
As of July 15, 2019, Tina Nørgaard has left the board of directors of DESITIN PHARMA A/S.
As of July 15, 2019, Alexander Arnkværn Berg is registered as director of DESITIN PHARMA A/S.
As of July 15, 2019, Tina Nørgaard has stepped down as adm. dir. of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2018. Gross profit came to DKK 6,012,108, and the net result was DKK 1,515,573.
As of March 1, 2018, Christian Eric Schmolck has joined the board of directors of DESITIN PHARMA A/S.
As of February 28, 2018, Hans-Jurgen Tacke has left the board of directors of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2017. Gross profit came to DKK 4,596,401, and the net result was DKK 629,530.
As of October 1, 2017, Tina Nørgaard has joined the board of directors of DESITIN PHARMA A/S.
As of October 1, 2017, Martin Schütt has joined the board of directors of DESITIN PHARMA A/S.
As of October 1, 2017, Dieter Heinrich Peitz has left the board of directors of DESITIN PHARMA A/S.
As of October 1, 2017, Michael Hanke has left the board of directors of DESITIN PHARMA A/S.
DESITIN PHARMA A/S has published its annual report for 2016. Gross profit came to DKK 5,603,913, and the net result was DKK 1,189,111.
DESITIN PHARMA A/S has published its annual report for 2015. Gross profit came to DKK 7,412,331, and the net result was DKK 2,362,269.
DESITIN PHARMA A/S has published its annual report for 2014. Gross profit came to DKK 957,551, and the net result was DKK 287,303.
DESITIN PHARMA A/S has published its annual report for 2013. Gross profit came to DKK 880,963, and the net result was DKK 208,832.
As of December 1, 2012, Tina Nørgaard is registered as adm. dir. of DESITIN PHARMA A/S.
As of December 1, 2012, Søren Lars Mikkelsen has stepped down as director of DESITIN PHARMA A/S.
As of September 9, 2008, J&P Invest, Kbh. ApS has been appointed auditor of DESITIN PHARMA A/S.
As of September 9, 2008, MONOGRAM SHOP ApS has stepped down as auditor of DESITIN PHARMA A/S.
As of October 18, 2001, Michael Hanke has joined the board of directors of DESITIN PHARMA A/S.
As of October 1, 2001, Michael Hanke has left the board of directors of DESITIN PHARMA A/S.
As of October 1, 2001, Søren Lars Mikkelsen is registered as director of DESITIN PHARMA A/S.
As of October 1, 2001, Hans-Jurgen Tacke has stepped down as director of DESITIN PHARMA A/S.
As of August 7, 1999, MONOGRAM SHOP ApS has been appointed auditor of DESITIN PHARMA A/S.
As of August 7, 1999, CJ Partnership I/S has stepped down as auditor of DESITIN PHARMA A/S.
As of October 30, 1998, Hans-Jurgen Tacke has joined the board of directors of DESITIN PHARMA A/S.
As of October 30, 1998, Michael Hanke has joined the board of directors of DESITIN PHARMA A/S.
As of October 30, 1998, Dieter Heinrich Peitz has stepped down as director of DESITIN PHARMA A/S.
As of July 1, 1996, CJ Partnership I/S has been appointed auditor of DESITIN PHARMA A/S.
As of July 1, 1996, Dieter Heinrich Peitz has joined the board of directors of DESITIN PHARMA A/S.
As of July 1, 1996, Dieter Heinrich Peitz is registered as director of DESITIN PHARMA A/S.
As of July 1, 1996, Hans-Jurgen Tacke is registered as director of DESITIN PHARMA A/S.
As of July 1, 1996, is registered as an owner of DESITIN PHARMA A/S with an ownership share of 100%.
DESITIN PHARMA A/S was founded on July 1, 1996.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 37626619
CVR 41183144
CVR 35451307
CVR 36392398
CVR 14479880
